Medical Advocates
Saquinavir (Fortovase/Invirase)
 
Perinatal Index

General Reports
 Monotherapy
 Combination Therapy
 Guidelines and Recommendations




 

 
Saquinavir Main Page ARV Drugs Main Page Home Page      
Last Update:  April 01, 2008
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
       

     Conference Reports, Abstracts, and Posters  

  Placental transfer of lopinavir, saquinavir, and ritonavir
 K Weizsaecker, C Feiterna, JP Siedentopf, et al
 [8th Int Congress on Drug Therapy in HIV Infection]
 Abstract
Monotherapy
       
Safety

          Journal Papers, Abstracts, and Commentaries

  Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional
lamivudine in pregnancy and prevention of vertical HIV transmission.
Vithayasai V, Moyle GJ, Supajatura V, et al.
J Acquir Immune Defic Syndr 2002 Aug 1;30(4):410-2
 Abstract		  

          Conference Reports, Abstracts, and Posters

  A Review of Protease Inhibitors (PI) Use in 89 Pregnancies
(6 CROI) 
Abstract  		  

Pharmacokinetics

          Journal Papers, Abstracts, and Commentaries

  FULL-TEXT PDF ARTICLE
 Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women
Acosta E, Zorrilla C, Van Dyke R, et al.
HIV Clin Trials 2001 Nov-Dec;2(6):445-52 
PDF Paper
 
          Conference Reports, Abstracts, and Posters
 
  CONFERENCE PDF POSTER
 The Pharmacokinetics of Saquinavir in New Tablet Formulation + Ritonavir (1000/100 mg
Twice Daily) in HIV-1-infected Pregnant Women
 D Burger, A Eggink, I Van der Ende, et al
 (14 CROI)
 PDF Poster    Abstract
       
SQV/RTV

          Journal Papers, Abstracts, and Commentaries
 
 
Clinical Response, Safety and Tolerability to Saquinavir with Low-dose Ritonavir in
HIV-1 Infected Mothers and their Infants: The PACTG 386.
 Zorrilla CD , Van Dyke R, Bardeguez A , et al
Antimicrob Agents Chemother. 2007 Apr 9;
 Abstract

Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency
Virus-Infected Pregnant Women.
 Acosta EP, Bardeguez A, Zorrilla CD, et al
Antimicrob Agents Chemother. 2004 Feb; 48(2): 430-436
 Abstract
 
       Conference Reports, Abstracts, and Posters
 
 
Pharmacokinetics (PK), safety, tolerability and efficacy of saquinavir 500mg tablets/ritonavir
(SQV/r) plus 2 nucleoside analogues (NRTIs) in HIV-pregnant women
Tung M.-Y., Boffito M., Taylor S, et al
 (Eighth International Congress on Drug Therapy in HIV Infection)
 Abstract

Pharmacokinetics (PK), safety, tolerability and efficacy of saquinavir hard-gel capsules/ritonavir
(SQV/r) plus 2 nucleosides in HIV-1-infected pregnant women
DA Hawkins, W Khan, GJ Moyle, et al
 (XV International AIDS Conference)
 Abstract
 
SQV/NNRTIs

          Journal Papers, Abstracts, and Commentaries
 
  Efficacy of Low-Dose Boosted Saquinavir Once Daily Plus Nucleoside Reverse Transcriptase
Inhibitors in Pregnant HIV-1-Infected Women With a Therapeutic Drug Monitoring Strategy.
 Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al
Ther Drug Monit. 2007 Apr;29(2):171-176.
 Abstract
Prevention/Treatment Guidelines and Recommendations
       
United States

     Internet Documents

  FULL TEXT PDF DOCUMENT
Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs
in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce
Perinatal HIV  Transmission in the United States.
Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
  FULL TEXT PDF DOCUMENT
Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy
 Perinatal HIV Guidelines Working Group.
November 2, 2007
Guidelines
 
                                                                                              
Saquinavir Main Page ARV Drugs Main Page Home Page      

SAQUINAVIR PERINATAL INDEX